Literature DB >> 12632426

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.

Giovanni Triolo1, Angelo Ferrante, Francesco Ciccia, Antonina Accardo-Palumbo, Antonino Perino, Antonio Castelli, Antonio Giarratano, Giuseppe Licata.   

Abstract

OBJECTIVE: To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL).
METHODS: We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the thirty-fourth week, and heparin at the thirty-seventh week. The primary outcome of interest was the rate of live births with the 2 treatments.
RESULTS: The characteristics of the 2 groups were similar at the time of randomization. The women treated with LMW heparin plus low-dose aspirin had a higher rate of live births (84%) than those treated with IVIG (57%).
CONCLUSION: Treatment with LMW heparin plus low-dose aspirin should be considered as the standard therapy for recurrent pregnancy loss due to aPL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632426     DOI: 10.1002/art.10957

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  33 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 3.  Treatment of the antiphospholipid antibody syndrome.

Authors:  Christopher Wu; Kenneth Kalunian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

Review 4.  Intravenous immunoglobulin therapy in antiphospholipid syndrome.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

5.  Management of antiphospholipid syndrome.

Authors:  Nicoletta Del Papa; Nikoleta Vaso
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

6.  Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome.

Authors:  Shigeki Shimada; Hideto Yamada; Tatsuya Atsumi; Takashi Yamada; Noriaki Sakuragi; Hisanori Minakami
Journal:  Reprod Med Biol       Date:  2010-06-15

Review 7.  Management of obstetric antiphospholipid syndrome.

Authors:  Guilherme Ribeiro Ramires de Jesus; Flavia Cunha dos Santos; Camila Souto Oliveira; Wallace Mendes-Silva; Nilson Ramires de Jesus; Roger Abramino Levy
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

8.  When conventional treatment fails: the role of intravenous immunoglobulin in recurrent pregnancy loss secondary to antiphospholipid syndrome.

Authors:  Jacklyn Chay; Karin Lust; Paul Kubler; Leonie Callaway
Journal:  Obstet Med       Date:  2013-05-03

Review 9.  Management of pregnancy in systemic lupus erythematosus.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

Review 10.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.